TCM
IMVT icon

Tyro Capital Management’s Immunovant IMVT Stock Holding History

Tyro Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-177,107
Closed -$3.03M – 14
2025
Q1 		$3.03M Buy
177,107
+25,651
+17% +$537K 1.13% 12
2024
Q4 		$3.75M Sell
151,456
-100,693
-40% -$2.86M 1.23% 13
2024
Q3 		$7.19M Buy
252,149
+1,529
+0.6% +$45.1K 2.32% 13
2024
Q2 		$6.62M Buy
250,620
+152,953
+157% +$4.35M 3% 14
2024
Q1 		$3.16M Buy
97,667
+52,667
+117% +$1.92M 1.82% 14
2023
Q4 		$1.9M Buy
+45,000
New +$1.66M 1.34% 13

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Tyro Capital Management's IMVT Position: Q2 2025 in Review

Tyro Capital Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 177,107 shares — an estimated $3.03M sold.

Tyro Capital Management first reported a position in IMVT in Q4 2023 and held it in 6 quarters. The position peaked at $7.19M in Q3 2024. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Tyro Capital Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Tyro Capital Management sold 177,107 Immunovant shares in Q2 2025, an estimated $3.03M.
  • Tyro Capital Management first reported a position in Immunovant in Q4 2023 and held it in 6 quarters.
  • Tyro Capital Management's Immunovant position peaked at $7.19M in Q3 2024.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Tyro Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.